Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VALTOCO vs DIASTAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GABA-A receptor positive allosteric modulator; increases chloride ion conductance, hyperpolarizes neurons, and suppresses seizure activity.
Diazepam enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, muscle relaxant, and anticonvulsant effects.
Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy aged 2 years and older
Status epilepticus (FDA-approved for acute management),Breakthrough seizures in patients on stable antiepileptic regimen (FDA-approved),Preoperative anxiety (off-label),Alcohol withdrawal syndrome (off-label),Muscle spasm (off-label)
5 mg, 10 mg, 15 mg, or 20 mg intranasally as a single dose based on weight; for patients weighing <50 kg: 5 mg, 10 mg for 50-75 kg, 15 mg for 75-100 kg, 20 mg for >100 kg. In adults, maximum dose is 20 mg per seizure cluster.
Adult: 0.2 mg/kg (max 20 mg) rectally as a single dose; may repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.
Terminal elimination half-life: 15-17 hours (range 11-20 h) in adults; no dose adjustment for age or renal impairment is recommended, but clinical monitoring is prudent in hepatic impairment.
30–60 hours for diazepam; nordazepam (active metabolite) 50–120 hours. Prolonged in elderly, liver disease, and neonates
Hepatic via CYP3A4 and CYP2C9; active metabolite desmethyldiazepam (nordazepam)
Primarily hepatic via CYP2C19 and CYP3A4; active metabolite desmethyldiazepam (with long half-life); minor pathways include glucuronidation.
Renal (70% as unchanged drug and metabolites, primarily glucuronide conjugate, with <2% as unchanged drug); biliary/fecal (30%)
Renal (primarily as glucuronide and sulfate conjugates; <5% unchanged), biliary/fecal minimal
96% bound, primarily to albumin
98–99%; primarily albumin
0.5-0.8 L/kg; approximates total body water, indicating extensive tissue distribution.
0.8–1.0 L/kg; increased in obesity (1.5–2.5 L/kg), redistribution to adipose tissue prolongs half-life
Intranasal: 75% (range 65-85%) relative to intravenous; rectal: 70-90% relative to intravenous.
Rectal: 90% (relative to IV, complete absorption). Oral: 100%
No dosage adjustment required for mild to moderate renal impairment. Severe renal impairment (e GFR <15 m L/min): consider using lower doses due to increased exposure; use with caution.
No specific dose adjustment required for renal impairment; however, use with caution in severe impairment (Cr Cl <10 m L/min) due to prolonged half-life.
Child-Pugh A or B: no adjustment needed. Child-Pugh C: reduce dose by 50% due to increased diazepam exposure.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Reduce dose by 75% or avoid use.
Age 6-17 years: 0.2 mg/kg intranasally, maximum single dose 20 mg. Administer as single dose per seizure cluster. Not recommended for children <6 years.
Children 2-5 years: 0.5 mg/kg (max 20 mg) rectally. Children 6-11 years: 0.3 mg/kg (max 20 mg) rectally. Children 12+ years: same as adult dosing. May repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.
Elderly patients may have increased sensitivity; consider starting at lower end of dosing range (5-10 mg) and titrate based on response and tolerability. Use with caution due to risk of sedation and falls.
Initiate at lower end of dosing range (e.g., 0.1-0.15 mg/kg, max 10 mg) due to increased sensitivity and risk of falls; monitor for prolonged sedation and respiratory depression.
WARNING: RISK OF RESPIRATORY DEPRESSION AND CARDIAC ARREST WITH CONCOMITANT USE OF ALCOHOL OR OTHER CNS DEPRESSANTS; RISK OF SUBSTANCE ABUSE, DEPENDENCE, AND WITHDRAWAL; WITHDRAWAL SEIZURES; AND RISK OF SERIOUS SKIN REACTIONS.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.
Risk of CNS depression and impaired motor function,Risk of abuse and dependence,Risk of withdrawal seizures upon abrupt discontinuation,Risk of serious skin reactions (e.g., Stevens-Johnson syndrome),Concomitant use with opioids may cause profound sedation, respiratory depression, coma, and death,Use in patients with compromised respiratory function or hepatic impairment requires caution
Risk of respiratory depression, especially with concomitant CNS depressants; tolerance and physical dependence may develop; withdrawal symptoms including seizures after abrupt discontinuation; caution in elderly, debilitated patients, and those with hepatic impairment; may cause drowsiness or dizziness; not recommended for use in pregnancy (neonatal withdrawal).
Hypersensitivity to diazepam or any component of the formulation,Acute narrow-angle glaucoma,Concomitant use with opioid analgesics for acute treatment of seizure clusters (unless alternative treatments are not available)
Known hypersensitivity to diazepam or any benzodiazepine; myasthenia gravis; severe respiratory insufficiency; severe hepatic insufficiency; sleep apnea syndrome; narrow-angle glaucoma (in patients receiving anticholinergic therapy).
No specific food interactions. Avoid alcohol consumption during VALTOCO use as it may increase CNS depressant effects.
No specific food interactions. Avoid grapefruit juice as it may increase diazepam levels. Alcohol can potentiate CNS depression.
Diazepam (active moiety in VALTOCO) is Pregnancy Category D. First trimester: Associated with increased risk of congenital malformations, particularly cleft lip/palate, when used chronically. Second and third trimesters: May cause fetal benzodiazepine exposure leading to floppy infant syndrome, neonatal withdrawal, and central nervous system depression. Late third trimester or delivery: Risk of neonatal respiratory depression, hypotonia, and feeding difficulties.
DIASTAT (diazepam) is classified as Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip and palate, when used during the first trimester. Second and third trimesters: Chronic use may lead to fetal dependence and withdrawal symptoms postnatally; risk of floppy infant syndrome (hypotonia, lethargy, sucking difficulties) when administered near term.
Diazepam is excreted into breast milk with an M/P ratio approximately 0.3. The relative infant dose is low (2-5% of weight-adjusted maternal dose). Caution is advised due to potential accumulation in neonates (long half-life) causing sedation, poor feeding, and respiratory depression. Use only if clearly needed with infant monitoring.
Diazepam is excreted into breast milk with an M/P ratio of approximately 0.2-0.5. The American Academy of Pediatrics recommends use with caution due to potential accumulation and sedation in the infant. Avoid chronic use; if necessary, monitor infant for sedation, poor feeding, and weight gain.
No specific dose adjustment recommended for VALTOCO during pregnancy for acute seizure management. However, due to increased volume of distribution and altered protein binding in pregnancy, a higher dose or more frequent dosing may be required for chronic use; clinical response should guide titration. Monitor for excessive sedation or respiratory depression as clearance may be reduced in late pregnancy.
Due to increased volume of distribution and altered protein binding in pregnancy, total clearance of diazepam may be increased, potentially requiring higher doses to achieve therapeutic effect. However, routine dose adjustment is not recommended without clinical monitoring. Use lowest effective dose for shortest duration. Caution in third trimester due to increased risk of neonatal effects.
VALTOCO (diazepam nasal spray) is indicated for acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) in patients with epilepsy aged 6 years and older. Administer one spray into one nostril; if needed, a second spray into the opposite nostril can be given after 4 hours if seizure activity persists. Do not use more than two doses per episode. Onset of action is rapid (within 2-5 minutes). Monitor for respiratory depression, especially in patients with compromised respiratory function or concomitant CNS depressants. Each spray delivers 5 mg or 10 mg diazepam; the dose depends on patient weight (5 mg for <40 kg, 10 mg for ≥40 kg). Tilt patient's head back slightly during administration. Do not reuse the device; discard after use.
DIASTAT (diazepam rectal gel) is a formulation for acute management of seizure clusters. Administer rectally; monitor for respiratory depression, especially with concomitant CNS depressants. Do not exceed 5 doses per month or use for more than 5 episodes per month due to tolerance risk. Have flumazenil available for reversal.
Use VALTOCO exactly as prescribed; only for seizure clusters, not for daily seizures.,Administer one spray into one nostril; do not prime the device.,After administration, tilt head back slightly and breathe normally.,If seizure activity continues after 4 hours, a second dose may be given in the opposite nostril.,Do not use more than two doses per seizure episode; if ineffective, seek emergency medical help.,Store at room temperature (20-25°C); protect from light and moisture.,Keep out of reach of children; discard device after use.,May cause dizziness, drowsiness, or coordination problems; avoid driving or operating machinery until effects wear off.,Inform healthcare provider of all medications, especially CNS depressants (e.g., alcohol, opioids, sedatives).,Do not consume alcohol while using VALTOCO.
Use only as directed for episodes of increased seizure activity.,Administer rectally; do not reuse diapers/suppositories.,Monitor for drowsiness, dizziness, or breathing problems.,Avoid alcohol and other CNS depressants.,Store at room temperature; protect from light.,Seek emergency care if seizures last longer than usual or breathing is difficult.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VALTOCO vs DIASTAT, answered by our medical review team.
VALTOCO is a Benzodiazepine Anticonvulsant that works by GABA-A receptor positive allosteric modulator; increases chloride ion conductance, hyperpolarizes neurons, and suppresses seizure activity.. DIASTAT is a Benzodiazepine Anticonvulsant that works by Diazepam enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, muscle relaxant, and anticonvulsant effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VALTOCO and DIASTAT depend on the specific clinical indication. These are both Benzodiazepine Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VALTOCO is: 5 mg, 10 mg, 15 mg, or 20 mg intranasally as a single dose based on weight; for patients weighing <50 kg: 5 mg, 10 mg for 50-75 kg, 15 mg for 75-100 kg, 20 mg for >100 kg. In adults, maximum dose is 20 mg per seizure cluster.. The standard adult dose of DIASTAT is: Adult: 0.2 mg/kg (max 20 mg) rectally as a single dose; may repeat once after 4-12 hours if needed. Maximum cumulative dose: 40 mg per 24-hour period.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VALTOCO and DIASTAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VALTOCO is classified as Category C. Diazepam (active moiety in VALTOCO) is Pregnancy Category D. First trimester: Associated with increased risk of congenital malformations, particularly cleft lip/palate, when used c. DIASTAT is classified as Category C. DIASTAT (diazepam) is classified as Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly cleft lip and palate, when used during the first. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.